A Phase 1 interventional study of XKH001 Injection and XKH001 Placebo Injection in Healthy Adult, sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD. Not yet recruiting at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Zhejiang Kanova Biopharmaceutical Co., LTD · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase Id, randomised, double-blind, placebo-controlled, multiple-dose, bridging study conducted at a single Phase I clinical research unit in Australia. The study is designed to evaluate the pharmacokinetics, safety, tolerability, and immunogenicity of XKH001 following repeated subcutaneous administration in healthy adult Caucasian participants, and to provide an ethnic-bridging pharmacokinetic comparison with the prior Phase I dataset in Chinese participants, required for XKH001's global development programme.
The study will consist of two cohorts of healthy adult Caucasian participants. Cohort 1 will receive XKH001 300 mg subcutaneously once every 4 weeks (Q4W) on Day 1, Day 29, and Day 57... Cohort 2 will receive XKH001 600 mg subcutaneously Q4W on Day 1, Day 29, and Day 57. Dosing will be initiated sequentially, with Cohort 1 (300 mg) dosed first, followed by Cohort 2 (600 mg). Dosing in Cohort 2 will not commence earlier than 21 days after the first participant in Cohort 1 receives the first dose and may proceed only following joint review of the available Cohort 1 safety data and unanimous agreement by the Sponsor's medical representative, the Medical Monitor, and the Principal Investigator A total of 16 healthy adult Caucasian participants will be enrolled in the study, with 8 participants per cohort. Within each cohort, participants will be randomised in a 3:1 ratio (6 active drug XKH001; 2 placebo) in a double-blind manner. Randomisation will be performed using a cohort-specific block randomisation schedule to maintain allocation concealment and treatment balance within each cohort. Enrolment will not be stratified by sex; however, at least 3 female participants will be enrolled in each cohort to ensure adequate female representation and to ensure that at least 1 female participant receives the investigational drug.
Zhejiang Kanova Biopharmaceutical Co., LTD is the lead sponsor of 6 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 will receive 300 mg XKH001 Injection or XKH001 Placebo Injection
Drug: XKH001 Injection · Drug: XKH001 Placebo Injection
Cohort 2 will receive 600 mg XKH001 Injection or XKH001 Placebo Injection
Drug: XKH001 Injection · Drug: XKH001 Placebo Injection
XKH001, developed by Zhejiang Kanova Biopharmaceutical Co., Ltd., is a recombinant anti-IL-25 humanized IgG1 monoclonal antibody (mAb) composed of two identical light chains and two identical heavy chains linked by disulfide bonds. Each light chain consists of 215 amino acids, and each heavy chain consists of 455 amino acids, for a total of 1340 amino acids.
Also known as: XKH001
Placebo;
Also known as: Placebo
Primary Outcome 1
Maximum observed serum concentration at steady state (Cmax,ss)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 2
Minimum observed serum concentration at steady state (Cmin,ss)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 3
Average serum concentration at steady state (Cavg,ss)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 4
Area under the serum concentration-time curve from time zero to the last quantifiable concentration at steady state (AUC0-t,ss)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 5
Area under the serum concentration-time curve from time zero to the theoretical infinite time at steady state (AUC0-inf,ss)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 6
Area under the serum concentration-time curve over one dosing interval at steady state (AUCtau)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 7
Time to maximum observed serum concentration at steady state (tmax,ss)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 8
Terminal elimination half-life at steady state (t½,ss)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 9
Mean residence time at steady state (MRTss)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 10
Terminal elimination rate constant (λz,ss)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 11
Percent of extrapolated area under the curve (%AUCex)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 12
Accumulation ratio based on Cmax and AUC (Rac)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 13
Apparent clearance at steady state (CLss/F)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 14
Apparent volume of distribution at steady state (Vz,ss/F)
Time frame: Day 1, Day 29, and Day 57
Primary Outcome 15
Incidence, severity, seriousness, and relationship to study treatment of treatment-emergent adverse events (TEAEs)
Time frame: first dose administration through Day 169
Primary Outcome 16
Incidence, severity, seriousness, and relationship to study treatment of treatment-emergent serious adverse events (SAEs)
Time frame: first dose administration through Day 169
Primary Outcome 17
Incidence, severity, seriousness, and relationship to study treatment of treatment-emergent adverse drug reactions (ADRs)
Time frame: first dose administration through Day 169
Primary Outcome 18
Incidence, severity, seriousness, and relationship to study treatment of treatment-emergent suspected unexpected serious adverse reactions (SUSARs)
Time frame: first dose administration through Day 169
Primary Outcome 19
Incidence and severity of local injection-site reactions following subcutaneous administration of XKH001 or placebo
Time frame: first dose administration through Day 169
Secondary Outcome 1
Incidence of anti-drug antibodies (ADA) to XKH001, including neutralising antibody (NAb) status for confirmed ADA-positive samples
Time frame: Day 1, Day 29, and Day 57, and during follow-up visits on Day 85, Day 113, and Day 169.
Secondary Outcome 2
Prevalence of anti-drug antibodies (ADA) to XKH001, including neutralising antibody (NAb) status for confirmed ADA-positive samples
Time frame: Day 1, Day 29, and Day 57, and during follow-up visits on Day 85, Day 113, and Day 169.
Secondary Outcome 3
Characterisation of anti-drug antibodies (ADA) to XKH001, including neutralising antibody (NAb) status for confirmed ADA-positive samples
Time frame: Day 1, Day 29, and Day 57, and during follow-up visits on Day 85, Day 113, and Day 169.
Other Pre-specified Outcomes1
Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including eosinophils
Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.
Other Pre-specified Outcomes2
Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including neutrophils
Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.
Other Pre-specified Outcomes3
Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including lymphocytes
Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.
Other Pre-specified Outcomes4
Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including monocytes
Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.
Other Pre-specified Outcomes5
Descriptive evaluation of routine laboratory pharmacodynamic (PD) biomarkers associated with type 2 inflammation, including total IgE.
Time frame: Day 1, Day 29, and Day 57, Day 85, Day 113, Day 169.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Apr 2027, 8 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: XKH001
Zhejiang Kanova Biopharmaceutical Co., LTD